top of page
About the Trial
PLN-74809, is an oral once daily antifibrotic being studied for the treatment of idiopathic pulmonary fibrosis (IPF).
Mechanism of Action:
αVβ1 and αVβ6 Inhibitor
Duration of Study
~58 Weeks
Phase
2
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Asvini Kulasingham, RRT
bottom of page